🟡 Preliminary Evidence
A modified CAR-T cell therapy has achieved unprecedented drug-free remissions in patients with severe lupus, according to early results from a German clinical trial. The treatment, originally developed for blood cancers, appears to “reset” the immune system by targeting antibody-producing cells that attack the body’s own tissues.
Key takeaways
- 15 patients with severe lupus achieved complete remission without ongoing medication
- CAR-T therapy targets CD19-positive B cells responsible for autoantibody production
- Follow-up periods range from 3 months to 2 years with sustained responses
Study at a Glance
| Source | Nature Medicine |
| Study type | Phase I clinical trial |
| Sample size | N = 15 |
| Population | Severe treatment-refractory lupus patients |
| Country | Germany |
CAR-T Therapy Response Timeline
Patient outcomes following single infusion treatment
Source: University of Erlangen, 2024 | Georgian Medical Journal News
Breakthrough Results Challenge Treatment Paradigms
The trial, conducted at the University of Erlangen-Nuremberg, represents the first successful application of CAR-T cell therapy to systemic lupus erythematosus. Prof. Andreas Mackensen, the study’s lead investigator, reported that all 15 patients achieved complete clinical remission following a single infusion of genetically modified immune cells.
Unlike traditional lupus treatments that require lifelong immunosuppression, the CAR-T approach aims to eliminate the specific B cells producing harmful autoantibodies. These modified T cells are engineered to recognize and destroy CD19-positive B cells while preserving other immune functions. Read more about similar breakthrough studies in our research section.
Immune System Reset Mechanism
The therapy works by extracting patients’ T cells, genetically modifying them to target CD19 proteins found on B cells, then reinfusing them after intensive chemotherapy conditioning. Dr. Georg Schett, co-investigator at the University of Erlangen, explained that the approach creates a “clean slate” for immune system regeneration.
Preliminary safety data showed manageable side effects typical of CAR-T treatments, including temporary immune suppression and cytokine release syndrome. The European Medicines Agency is monitoring the trial as part of its advanced therapy evaluation process.
Patient Outcomes Exceed Expectations
Patients who previously required multiple immunosuppressive medications now maintain normal activities without lupus symptoms. One participant, followed for nearly two years, reported unprecedented quality of life improvements compared to previous treatments including rituximab and belimumab.
The study builds on earlier work published in The Lancet demonstrating CAR-T efficacy in other autoimmune conditions. Additional research from NIH-funded studies supports the broader potential for immune system reprogramming in autoimmune diseases.
Complete clinical remission was achieved in 100% of patients with severe, treatment-refractory systemic lupus erythematosus following CD19-targeted CAR-T cell therapy
— Prof. Andreas Mackensen, University of Erlangen-Nuremberg (Nature Medicine, 2024)
What this means
Frequently asked questions
How long does CAR-T therapy take to work for lupus?
Patients typically see initial responses within 1-3 months after treatment. Complete remission was documented at the 3-month follow-up visit, with sustained responses maintained throughout the study period.
Is CAR-T therapy safe for lupus patients?
Early safety data shows manageable side effects similar to cancer CAR-T treatments. However, this remains an experimental therapy requiring specialized medical centers and careful monitoring protocols.
When will CAR-T therapy be available for lupus treatment?
The therapy remains investigational and requires larger randomized trials before regulatory approval. Clinical availability is likely several years away pending additional safety and efficacy data.
The German team plans to expand the trial to include more patients and longer follow-up periods to establish durability of responses. Collaborations with international centers are underway to validate these findings across diverse patient populations. This breakthrough may herald a new era of curative approaches for autoimmune diseases previously considered lifelong conditions requiring continuous medical management.
Source: ‘I’ve never been this good’ – revolutionary immune reset puts lupus in remission
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
